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Abstract
Background: Polycystic ovarian syndrome (PCOS) is a common female endocrine disorder with unknown
etiology. Many treatments are available to treat the symptoms associated with this condition including obesity,
insulin resistance, abnormal glucose metabolism, infertility, menstrual irregularity, hirsutism, and acne
vulgaris. More recently, it has been found that women with PCOS, particularly if obese, are more likely to be
vitamin D deficient. It is hypothesized that vitamin D and calcium metabolism can also affect symptoms
associated with PCOS as it influences many physiologic processes within the body. Does vitamin D and
calcium supplementation improve symptoms of PCOS?
Methods: An exhaustive medical literature search was conducted using Medline-OVID, CINAHL, EBMR
Multifile, GoogleScholar and Web of Science using keywords: polycystic ovarian syndrome and vitamin D.
The search was further narrowed to include articles with English language and humans only. For included
articles, bibliographies were screened for relevant articles. Included articles were evaluated using GRADE.
Results: For this review, the final number of relevant, primary articles meeting inclusion criteria was a total of
6 articles. These articles included two randomized- controlled trials, three observational studies, and one case-
control study. These studies vary in sample size, measurement of outcomes, population selection, and
significance in results. Multiple studies suggest improvement in menstruation regularity, fertility, BMI, insulin
resistance, glucose metabolism, and hyperandrogenism; but the studies evaluated have many limitations and
yield insignificant observations.
Conclusion: It is possible that vitamin D and calcium supplementation yields a good outcome in a variety of
symptoms common in PCOS, but evidence is lacking in quality. A weak recommendation for vitamin D and
calcium supplementation can be made as vitamin D is relatively inexpensive and safe. A stronger
recommendation is made if PCOS patients are vitamin D deficient. Long-term, randomized clinical studies
need to be conducted to determine whether vitamin D and calcium supplementation is necessary in the
treatment of PCOS and to demonstrate the benefits of supplementation in relation to the general population
with this condition.
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Abstract   
 
Background: Polycystic ovarian syndrome (PCOS) is a common female endocrine disorder with 
unknown etiology. Many treatments are available to treat the symptoms associated with this 
condition including obesity, insulin resistance, abnormal glucose metabolism, infertility, 
menstrual irregularity, hirsutism, and acne vulgaris. More recently, it has been found that women 
with PCOS, particularly if obese, are more likely to be vitamin D deficient. It is hypothesized that 
vitamin D and calcium metabolism can also affect symptoms associated with PCOS as it 
influences many physiologic processes within the body. Does vitamin D and calcium 
supplementation improve symptoms of PCOS? 
Methods:  An exhaustive medical literature search was conducted using Medline-OVID, 
CINAHL, EBMR Multifile, GoogleScholar and Web of Science using keywords: polycystic 
ovarian syndrome and vitamin D. The search was further narrowed to include articles with 
English language and humans only. For included articles, bibliographies were screened for 
relevant articles. Included articles were evaluated using GRADE. 
Results:  For this review, the final number of relevant, primary articles meeting inclusion criteria 
was a total of 6 articles. These articles included two randomized- controlled trials, three 
observational studies, and one case-control study. These studies vary in sample size, 
measurement of outcomes, population selection, and significance in results. Multiple studies 
suggest improvement in menstruation regularity, fertility, BMI, insulin resistance, glucose 
metabolism, and hyperandrogenism; but the studies evaluated have many limitations and yield 
insignificant observations. 
Conclusion: It is possible that vitamin D and calcium supplementation yields a good outcome in 
a variety of symptoms common in PCOS, but evidence is lacking in quality. A weak 
recommendation for vitamin D and calcium supplementation can be made as vitamin D is 
relatively inexpensive and safe. A stronger recommendation is made if PCOS patients are vitamin 
D deficient. Long-term, randomized clinical studies need to be conducted to determine whether 
vitamin D and calcium supplementation is necessary in the treatment of PCOS and to demonstrate 
the benefits of supplementation in relation to the general population with this condition. 
Keywords:  polycystic ovarian syndrome, vitamin D, calcium 
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Improvement of Symptoms in Patients With Polycystic Ovarian Syndrome by 
Vitamin D and Calcium Supplementation 
BACKGROUND 
 
Polycystic ovarian syndrome (PCOS) is a frustrating condition for affected 
women and one that is found particularly hard to treat by providers. An estimated 4 to 12 
percent of women in the United States have PCOS.1 The Rotterdam criteria define the 
syndrome in patients who have two of three of the following: chronic oligomenorrhea or 
amenorrhea, evidence of androgen excess or polycystic ovaries.2 Classical features of 
PCOS include, but are not limited to; infertility, hyperandrogenism, truncal obesity, 
abnormal glucose metabolism, insulin resistance (IR), hirsutism, and acne vulgaris. 
Symptoms typically manifest in early puberty and worsen with maturation. Nearly 80 
percent of patients affected present with more than one symptom.3  
The primary etiology of PCOS has not yet been determined, but it is known that 
many metabolic disturbances occur within this disease and cause associated symptoms. It 
is hypothesized that dysfunction of glucose and insulin metabolism leads to increasing 
symptoms of androgen excess, which in turn, results in worsening of metabolic function 
and obesity. Increased weight gain is attributed to IR and induces more hyperandrogenic 
effects.4 Insulin resistance leads to hyperinsulinemia,5 more consistently in obese PCOS 
patients.4 As a result, increased insulin promotes secretion of androgens from the ovaries 
and decreases the amount of serum sex hormone-binding globulin (SHBG); therefore, 
serum free testosterone is elevated.3 Other hormones such as luteinizing hormone (LH), 
follicle stimulating hormone (FSH), estrogen and other androgenic derivatives are 
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negatively affected.3 Ovarian follicle growth and maturation is altered by 
hyperinsulinemia and androgen excess,5 causing menstrual irregularity and infertility.  
It is newly accepted that these metabolic changes are related to dysfunction of 
vitamin D and calcium metabolism, which is also important in follicular development6 
and normal glucose metabolism.7 Multiple studies have shown that PCOS patients, 
particularly if obese, have lower serum vitamin D levels.4,8-10 Because vitamin D is fat 
soluble, it is likely that a larger than normal percentage of available vitamin D is 
requisitioned into adipose tissue, causing decreased serum levels in obese patients.11 
Lower vitamin D levels have been associated with hyperandrogenism,4,10,11 metabolic 
syndrome,9 insulin resistance,4,9,10,12 and increased body mass index (BMI).4,10,12,13 
Physiologic functions of active vitamin D that affect glucose and insulin metabolism 
include producing insulin from pancreatic beta cells, augmenting insulin sensitivity by 
increasing expression of the insulin receptor, and decreasing release of cytokines that 
facilitate IR.14 One study found significant correlation between hirsute women with 
PCOS and lower vitamin D levels.9 Other studies have not agreed with these findings, 
suggesting lack of research and validity in regards to the results. Limited evidence has 
shown that vitamin D and calcium metabolism affects oocyte maturation and production 
of androgens, but one research study revealed that 1,25-dihydroxyvitamin D mediates an 
enzyme known as aromatase which converts androgen derivatives to estrogen in 
granulosa cells of the ovaries.15 Therefore, dysfunction in this mechanism affects the 
menstrual cycle and ovulation by altering the hormone levels mediated and suppressed by 
estrogen, LH, and FSH.  
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To validate some of these outcomes, researchers have experimented in treating 
PCOS patients with vitamin D and calcium supplementation. This systematic review is to 
evaluate the current evidence and make recommendations as to whether vitamin D and 
calcium supplementation improves symptoms in PCOS patients. 
METHODS 
 
An exhaustive medical literature search was conducted using Medline-OVID, 
CINAHL, EBMR Multifile, GoogleScholar and Web of Science using keywords: 
polycystic ovarian syndrome and vitamin D. The search was further narrowed to include 
articles with English language and humans only, as well as articles published from 
January 1990 to August 2012. Articles using vitamin D supplementation with or without 
calcium supplementation were included. Primary articles evaluating vitamin D in 
addition to fertility treatment (i.e. Clomiphene) were excluded from review. For included 
articles, bibliographies were screened for additional relevant resources. Relevant articles 
were appraised for quality, validity, and risk of bias using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE).16   
 
RESULTS 
 
The preliminary search throughout all databases yielded 45 articles for review. 
The final number of relevant, primary articles meeting inclusion criteria was a total of 6 
articles. These articles included two randomized- controlled trials (RCT),17,18 three 
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observational studies,6,19,20 and one case-control study.7  Results and summaries of these 
studies are also demonstrated on Table I. 
 
Rashidi et al 
This randomized clinical trial (pilot study)17 evaluated the effects of calcium and 
vitamin D supplementation in PCOS on Metformin therapy. For this study, all patients 
were referred to the Vali-e-Asr Reproductive Research Center. Sixty Iranian, infertile 
PCOS patients aged 20 to 40, were selected to participate if they met 2 of 3 of the 
Rotterdam criteria for PCOS. Primary outcomes included BMI, menstruation regularity, 
follicular size, and pregnancy rates. Secondary outcomes included review of dietary 
consumption questionnaires and patient recall of diet intake, particularly information of 
dairy, protein, and fat consumption. Changes in serum vitamin D levels were not 
evaluated.17 
Notable exclusion criteria included history of endocrine disorders, primary 
hyperparathyroidism or hyperprolactinemia, hormone secreting tumor of androgenic 
nature, prior history of abdominal or pelvic surgery, coexisting male factor infertility, or 
history of abnormal ultrasound of the uterus and salpinges. All participants completed 
physicals including transvaginal ultrasound to determine the presence of polycystic 
ovaries and follicle diameter and questionnaires regarding diet consumption. Biochemical 
markers such as serum and urine calcium, FSH, LH, prolactin, and serum magnesium 
were evaluated in all patients for homogeneity.17  
Patients were randomly separated into three groups by a random number table 
with 20 patients in each group. A statistical method known as analysis of variance 
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(ANOVA) determined no significant difference in characteristics amongst participants 
within the selected groups.  Group 1 received 1 000 mg of calcium and 400 IU vitamin D 
daily (Calcium-D tab 500 mg  200 IU; Tehran Darou, Iran). Group 2 was similar to 
Group 1, except for the addition of 1 500 mg daily of Metformin (Metformin tab 500 mg; 
Minoo Darou, Iran). Group 3 members were given Metformin 1 500 mg daily without 
other supplementation. All treatments were received for 3 months, and follow up 
included an additional 3 months after therapy.17 
Results demonstrated an increase in size and number of follicles >/= 14 mm after 
follow up in patients who had received calcium and vitamin D supplementation (Group 
2) in addition to Metformin, compared to other groups (Group 2 vs Group 1, P = 0.0372, 
Odds Ratio (OR) = 2.01; Group 3 vs Group 1, P = 0.2896; No OR provided). Six months 
after therapy, Group 2 showed continued treatment response compared to other groups 
(number needed to treat (NNT) = 9.5). Chi-squared tests showed no significance in 
positive changes in menstruation (P = 0.400, NNT = 6.7) and follicular stimulation (P = 
0.2896). A subgroup analysis of three BMI groups ( <25, 25-27, >27), showed no 
significant difference in menstruation regularity and BMI. No pregnancy occurred in the 
three study groups. Analysis of diet through Kruskal-Wallis test revealed that the 
majority of participants (60%) were below recommendations for dairy intake.17 
The authors recognized limitations in sample size and suggest a larger sample size 
may prove results to be more significant. A small loss to follow up was noted in each 
study group with no reasons provided by the authors. The conclusion of this study was 
that vitamin D and calcium supplementation in addition to Metformin had a more 
successful treatment effect on menstrual regulation and follicular development.17 
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Thys-Jacobs et al 
This observational study6 investigated whether diminished calcium and vitamin D 
regulation affects follicular development in 13 premenopausal women with PCOS. There 
is no documentation of location and setting to which the study takes place. Patients were 
ages 21 to 41 and included in the study if they met the National Institute of Health (NIH) 
Consensus Criteria of PCOS: chronic oligomenorrhea/anovulation and signs of 
hyperandrogenism; including acne vulgaris, hirsutism, and alopecia. Two patients were 
Caucasian and 11 patients were Hispanic. All patients presented with hirsutism; 5 
patients had acanthosis nigricans, 2 with alopecia, and 3 with acne vulgaris. Nine of 
thirteen participants had polycystic ovaries. Primary outcomes included follicular 
development, menstruation regularity, and androgenic changes.6 
Exclusion criteria included any androgen secreting tumors, Cushing’s syndrome, 
hyperprolactinemia, primary hyperparathyroidism, cancer, history of gastrectomy, renal 
failure, inflammatory bowel disease, use of anti-seizure medications and mental 
retardation. If adrenal hyperplasia was detected later in the study and by an 
adrenocorticotropic hormone (ACTH) suppression test, patients were excluded from the 
study. It is not described whether or not patients were on or excluded for concomitant 
medications. Participants underwent history and physical evaluations and laboratory 
analysis for prolactin, dihydroxyepiandrosterone sulfate (DHEAS), 17-
hydroxyprogesterone, androstenedione, AM cortisol, total testosterone, LH and FSH. 
Other laboratory tests for baseline included total calcium, intact parathyroid hormone 
(PTH), 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. A transvaginal sonogram 
was obtained for each patient to evaluate for polycystic ovaries.6 
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All patients were placed on 1 500 mg daily of calcium carbonate and 
ergocalciferol (vitamin D) 50 000 units weekly or biweekly for 6 months. Vitamin D 
levels improved in all patients within 3 months of therapy. Within two months of therapy, 
9 of 13 patients had normalized their menstrual cycles, defined as 27 to 32 days of cycle 
length. Two patients had resolution of dysfunction uterine bleeding and two other women 
became pregnant. After 6 months of therapy, acne presentation improved in affected 
patients but no other improvements related to androgen excess were observed.6  
No limitations of this study were discussed. This study concluded that calcium 
and vitamin D supplementation enhances menstruation regularity and elucidates the 
possibility that this therapy could correct abnormal follicular development.6  
 
Firouzabadi et al 
One-hundred Iranian, infertile PCOS patients, aged 20 to 40, were enrolled in this 
case-control study.7 Participants were randomized into 2 groups (n=50) via random 
number table. All portions of the study were conducted at Shahid Sadoughi University of 
Medical Sciences, Department of Obstetrics and Gynecology, Research and Clinical 
Center for Infertility. All patients were selected to participate if they met 2 of 3 of the 
Rotterdam criteria for PCOS. Evaluated outcomes included menstruation regularity, 
changes in BMI, follicular size, pregnancy rate, and vitamin D levels. There were no 
significant differences of patient characteristics between groups.7 
Patients with Cushing’s syndrome, hyperprolactinemia, renal failure, any type of 
androgen secreting tumor, primary hyperparathyroidism, cancer, history of gastrectomy, 
inflammatory bowel disease, anti-seizure medications, and mental retardation were 
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excluded from the study. Patients underwent history and physical examination, 
transvaginal ultrasound, and diagnostic lab analysis of hormones including LH, FSH, 
serum calcium, and vitamin D levels (25(OH)D).7 
Group 1 received 1 500 mg daily of Metformin (Metformin tab, 500 mg; Osvah 
Pharmaceutical Company), and Group 2 was treated with 1 000 mg daily of calcium 
(Tablet 500 mg; Sobhandarou Pharmaceutical Company) and vitamin D (Pearl Vitamin 
D3, 50 000 IU/week; Zahravi Pharmaceutical Company) 100 000 IU monthly in addition 
to 1 500 mg daily of Metformin for 6 months.7   
The study revealed a more significant decrease in BMI in the treatment group 
(Group 2, P = 0.054). A notable improvement in menstrual regularity after 6 months of 
therapy in Group 1 (58%) vs Group 2 (70%) was observed, but Chi-square analysis 
proved this outcome insignificant between study groups (P = 0.211, NNT = 8.3). Less 
significant changes in follicular maturation were noted between study groups at three and 
six months after therapy (P = 0.759 and P = 0.698, respectively). Although more 
pregnancies occurred in Group 2 than Group 1 (18% vs 12%), there was no significance 
in pregnancy rates between the two groups (P = 0.401, NNT = 16.7). A Chi-square 
analysis within each group comparing before and after treatment showed significant 
effect on menstrual regularity, BMI, and follicular response (P = 0.001). Vitamin D levels 
improved substantially and were significant when comparing Group 2 to Group 1, which 
did not receive vitamin supplementation (P </= 0.001).7 
The authors noted lack of a control group as a limitation in the study and 
discussed the fact that Iranian women are at increased risk for vitamin D deficiency due 
to cultural and location factors: clothing, environment, prevention of sun exposure and/or 
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increased approaches to avoid sun exposure.18 This study states vitamin D and calcium 
supplementation can improve weight reduction, follicular development, improvements of 
androgen access symptoms, and regularity of menses in vitamin D deficient PCOS 
patients. The authors also suggested that vitamin D supplementation could be a potential 
treatment in improving IR and infertility associated with PCOS.7 
 
Ardabili et al 
This double-blinded, placebo-controlled randomized clinical trial19 evaluated the 
effects of vitamin D supplementation on glucose levels and insulin resistance. Sixty 
vitamin D deficient, PCOS patients recruited from an outpatient clinic at Alzahra 
Hospital of Tabriz University of Medical Sciences in Iran were included in the study. 
Patients must to have been diagnosed with PCOS as characterized by having met 2 of 3 
symptoms of the Rotterdam criteria, vitamin D deficient (<20 ng/mL), and between 20 
and 40 years of age.  The primary outcomes of the study were glucose metabolism, 
insulin resistance, and insulin sensitivity. A secondary outcome was assessment of 
dietary intake through a 3-day recall from each participant.19 
This study’s exclusion criteria consisted of any patients with an androgen 
secreting tumor, Cushing’s syndrome, congenital adrenal hyperplasia, 
hyperprolactinemia, and/or virilism. Other characteristics were also considered: history of 
impaired fasting glucose or diabetes, thyroid disorders, liver disease, renal disease, and 
cardiovascular disease. Any patients that took medications that affect the hormone 
system, such as metformin or corticosteroids, or taking vitamin D and calcium 
supplementation, were excluded from the study. All participants had examinations and 
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evaluation of height and body weight. Also, patients gave blood samples to evaluate 
PTH, glucose, insulin, vitamin D (25(OH)D) levels before and after treatment.19 
Patients were randomized into two groups, receiving 3 doses of 50 000 units 
vitamin D3 (D-Vitin 50 000 IU; Zahravi Pharm Co, Tabriz, Iran) or placebo (Zahravi 
Pharm Co) in 2 months. Covariance analysis showed no significant difference between 
study groups.  The appearance of treatment and placebo, including packaging, were 
identical to ensure blinding. Follow up consisted of assessment of compliance with 
interviews, pill monitoring, and telephone calls. Noncompliant patients were excluded 
from the study. With loss to follow up and noncompliance, 24/30 participants completed 
the study in the treatment group and 26/30 participants completed in the placebo group.19  
This study demonstrated improvements in vitamin D levels, PTH levels, and 
insulin secretion in the experimental group, but it was not significant to placebo. 
Homeostasis Model of Assessment (HOMA)-IR, a measurement for IR, did not change 
significantly before and after treatment between groups (3.17 +/- 4.08 to 3.21 +/- 2.59, P 
= 0.42). HOMA-B, an assessment of beta cell function, showed an increase in the 
treatment group, but it was not significant when compared to placebo (120.5 +/- 120.4 to 
152.5 +/-97.49, P = 0.01). Insulin sensitivity measures, HOMA-S, was not significant in 
the treatment group (0.79 +/- 1.49 to 0.59 +/- 0.91, P = 0.26). A quantitative insulin 
sensitivity check index (QUICKI) also revealed no significant impact on insulin 
sensitivity in the treatment group (0.347 +/- 0.059 to 0.337 +/- 0.046, P = 0.14). Serum 
vitamin D levels increased in the treatment group (6.9 +/- 2.8 to 23.4 +/- 6.1 ng/mL, P < 
0.0001) and serum PTH levels decreased (70.02 +/- 43.04 to 50.033 +/- 21.99 
microIU/mL, P = 0.02). The result of this analysis concluded there was no correlation 
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between vitamin D levels and IR or insulin sensitivity. Significance of the results did not 
change with loss to follow up.19  
Noted limitations by the authors include short follow up duration, not using the 
glucose clamp method to accurately evaluate insulin sensitivity and secretion, and form 
and low dosage of vitamin D supplementation. The study concluded that vitamin D may 
not have a significant impact on insulin resistance and sensitivity in PCOS patients with 
vitamin D deficiency.19 
 
Kotsa et al 
This observational study20 assessed the effect of vitamin D supplementation on 
glucose metabolism in obese PCOS patients. Patients were recruited from an outpatient 
clinic in Greece and included participants who were aged 20 to 40 with history of PCOS 
and IR. In this study, PCOS is defined as chronic anovulation (fewer than 6 cycles in 12 
months) and clinical or/and laboratory finding of androgen excess. Other inclusion 
criteria included a family history of diabetes mellitus, type II and BMI>30. Patients were 
to refrain from hormone altering medications for two months prior to enrollment. To 
enroll into the study, patients also had to complete a one-month diet containing 1 500 mg 
of calcium daily. Primary outcomes included peripheral insulin resistance and increased 
insulin effectiveness. Secondary outcomes were BMI and PTH levels.20 
Exclusion criteria included any other condition causing hyperandrogenism, 
menstrual dysfunction, and virilism. All participants had laboratory analysis of glucose, 
insulin, PTH, calcium, phosphorus, vitamin D (25(OH)D) level, triglycerides, high 
density lipoprotein (HDL), and low density lipoprotein (LDL) at baseline and after 
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treatment completion. Transvaginal sonography was not conducted to evaluate presence 
or absence of polycystic ovaries or follicle size.20   
All fifteen patients received 1 microgram of Alphacalcidol (1-alpha-
hydroxyvitamin D3) daily for 3 months. No significant changes in serum glucose and 
insulin levels were observed after therapy. Serum 25(OH)D level improved significantly 
with treatment (15.15 +/- 1.84 to 28.62 +/- 1.65 ng/mL, P < 0.0001). Serum PTH levels 
decreased significantly after therapy (40.2 +/- 3.92 to 32 +/- 1.99, P < 0.006). First phase 
area under the curve (AUC) increased significantly with treatment (763 +/- 60.89 to 
834.67 +/- 71.99 microU/mL, P < 0.0001). Also, first phase AUC for glucose decreased 
substantially (2,298.8 +/- 71.99 to 2,182.73 +/- 73.53 mg/dL, P < 0.05). Although there 
was an observed increase in insulin sensitivity, it was not significant (P = 0.1); but there 
was notable significance in insulin effectiveness (P < 0.01). Vitamin D levels were 
inversely correlated with insulin effectiveness (P = 0.09) and insulin secretion (P < 
0.0001). No change in BMI was observed in the study.20 
Notable limitations to this study include small sample size, short follow up 
duration, and no control group. All study participants were obese, so there is a potential 
for bias as the study participants are more likely to have glucose and insulin metabolism 
dysfunction. Baseline information for one participant was not included in the study data. 
The conclusion of this study was that vitamin D supplementation has beneficial effects in 
insulin sensitivity and effectiveness, and overall, improves glucose metabolism.20 
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Selimoglu et al 
In this randomized, observational study21, the researchers investigated the effects 
of vitamin D supplementation on IR, glucose metabolism, and hyperandrogenic features 
associated with PCOS. A total of 11 insulin resistant, obese PCOS patients were enrolled 
into the study. Patients were recruited from the Endocrinology and Metabolism Division 
of Medical School of Uludag University Bursa, in Turkey. For inclusion in the study, 
PCOS was defined as clinical and/or laboratory diagnosis of hyperandrogenism, 
oligomenorrhea or amenorrhea (cycles longer than 35 days or less than 2 cycles in 6 
months, respectively), and polycystic ovaries. Study participants also had to be between 
ages 18 to 35 and have a BMI greater than 25.21 
Any patients with other causes of hyperandrogenism or hormone dysfunction or 
virilism were excluded from the study. Other exclusion criteria included history of 
diabetes mellitus type II, thyroid disease, major organ dysfunction (i.e. liver, heart, 
kidney) or intake of hormone altering medications that might affect vitamin D 
metabolism or glucose metabolism. All participants had laboratory analysis of serum 
glucose, insulin, 25(OH)D, androgen biomarkers, LH, FSH, estrogen and progesterone 
levels, and calcium and phosphorus before and after therapy. A Ferriman – Gallwey score 
(FG) for hirsutism was assessed by two endocrinologists, and patients were considered 
hirsute if the score was >/= 6. Each patient was also evaluated with pelvic ultrasound.21 
All 11 PCOS patients received one dose of 300 000 units of vitamin D (Devit 3 
amp 300,000 IU, Deva Iiac, Turkey) to determine the effects of supplementation on 
glucose metabolism, hyperandrogenism, and insulin resistance. Three weeks after 
therapy, analysis showed improvement in serum 25(OH)D levels (16.9 +/- 16.0 to 37.1 
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+/- 14.6 ng/mLm, P= 0.027), decreased in HOMA-IR (4.41 +/- 1.38 to 3.67 +/- 1.48, P = 
0.043). Although there were decreases in serum insulin and glucose, the results were not 
significant. There were also small decreases in free testosterone levels, but they were also 
not significant (3.10 +/- 1.64 to 1.96 +/- 1.49 pg/mL, P = 0.09). No changes in other 
androgen levels or relationship between vitamin D and HOMA were noted.21  
The limitations of this study included small sample size, short follow up duration, 
and short duration for treatment effect or lack of treatment. The conclusion of this study 
is vitamin D supplementation improves insulin resistance in obese PCOS patients with 
vitamin D deficiency, and recommends administration of vitamin D supplementation to 
this population of patients to prevent onset of diabetes mellitus type II or IR development 
and progression. They also inquire about the possibility of vitamin D supplementation to 
improve hirsutism.21 
DISCUSSION 
 
The combined vitamin D and calcium supplementation shows potential in 
improving various symptoms and features associated with PCOS. Positive effects were 
demonstrated in fertility, menstruation regulation, BMI, IR, and glucose metabolism, and 
less so in hyperandrogenic characteristics; but quality of evidence is still lacking and 
results between studies appear inconsistent. This may be due to population selection, 
small sample size, differences in measuring outcomes, duration of treatment, differences 
in treatment, and differences in study methodology.  
Various studies have shown an increased proportion of PCOS patients with 
vitamin D deficiency, particularly if obese. There is no current recommendation for 
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vitamin D supplementation in this patient population and it is not common practice to 
evaluate patients for vitamin D deficiency, which should also be considered in the 
management of this condition. 
In current practice, PCOS treatment involves weight management, correction of 
menstrual irregularity, monitoring and preventing of glucose metabolism and insulin 
resistance, and if necessary, fertility treatment. Weight loss has been associated with 
improvement of insulin resistance and menstrual regularity. Adipose tissue has the 
capacity to hold on to additional estrogen, so a decrease in weight and adipose loss results 
in altercation of hormones that affects the menstrual cycle and improves menstrual 
regularity. Oral contraceptives, more specifically medications with anti-androgenic 
properties, are chosen to improve menstrual regulation and hirsutism. Unlabeled use of 
Metformin, a diabetes medication used to increase insulin sensitivity, improves IR and 
ovulation. As a result, it affects androgenic hormones and can also improve clinical and 
biological signs of hyperandrogenism. Fertility agents that induce ovulation are another 
option for those seeking pregnancy. Due to its physiological function, it is possible that 
vitamin D supplementation may have a beneficial treatment effect in improving 
symptoms of PCOS.  
Fertility is a critical patient outcome that is commonly addressed in managing 
PCOS patients. Vitamin D supplementation has potential to alter folliculogenesis and 
response of the developing follicle,6,7,17 as observed in studies within this review. Several 
studies suggest calcium metabolism dysfunction upsets oocyte development and 
therefore, fertility6. As a result, vitamin D deficiency may alter the availability and 
function of calcium, suggesting that vitamin D supplementation could correct this 
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imbalance. Menstrual irregularity improved with vitamin D and calcium 
supplementation.6,7,17 Across studies within this review, there are inconsistent findings 
regarding insulin resistance, insulin sensitivity, and glucose metabolism.7,19-21 Evidence 
suggests that lower vitamin D levels are inversely correlated with higher BMI,4,10 so 
vitamin D supplementation could potentially assist in weight management in PCOS. 
There is limited evidence that vitamin D supplementation improves symptoms of 
androgen access.6,7,21 Although there is beneficial potential to vitamin D supplementation, 
current evidence is lacking in reproducibility and quality. A summary of findings 
demonstrates important flaws and limitations noted amongst each study within this 
review (Table I).  
In general, multiple studies within this review were conducted in the Middle East 
with participants being from Iran,7,17,19 Greece,20 and Turkey.21These populations have 
very large cultural influences on environment, activity, food, and clothing; which could 
impact the severity of vitamin D deficiency and PCOS. Other differences between studies 
include type of vitamin D supplementation and whether participants were on other 
medications like Metformin or calcium supplements. Each study has been downgraded 
quality of evidence and therefore, the quality of evidence is graded as very low by 
GRADE criteria. 
Rashidi et al17 has no details of blinding and allocation and used a surrogate 
outcome to correlate with pregnancy rates not observed in results. There was a lack of 
treatment and follow up for the outcome of pregnancy, which was not discussed by the 
authors. The small loss to follow up may have affected the results of this study as the 
population sample size was small. In this study menstrual regulation, diet, and pregnancy 
Page 23 of 31 
 
had objective measurements, so it is downgraded for recall bias. As with multiple studies 
assessing fertility,6,7,17 a possible confounder is no recording of sexual activity for the 
outcome of pregnancy. If patients are not sexually active or are limited in sexual activity, 
then pregnancy rates are likely affected and variation would be noted between 
participants. 
Thys-Jacobs et al6 has no control population and flawed measurement of 
hyperandrogenism due to objectivity, therefore indicating recall bias. Other studies used 
more specific evaluations and scoring criteria to evaluate for clinical and biochemical 
androgen access. Menstrual regularity was also a patient-related outcome that was 
assessed by patients objectively and short length for this outcome, also illustrating recall 
bias and lack of treatment for this outcome. Other limitations in this study include small 
population size and use of NIH criteria rather than Rotterdam criteria; although they 
share similar characteristics that diagnose PCOS. In this study, patients did not receive 
Metformin in conjunction with vitamin D and calcium supplementation like other studies 
included in this review.19-21 
Firouzabadi et al7 is a case-control study without blinding, has large confidence 
intervals (CI), and incomplete account for outcome. In the baseline evaluation, one 
patient was not shown to have baseline results. Similar to Thys-Jacobs et al6, this study 
did not include a quality measurement for hyperandrogenic features. The population 
selected was also varied with no control group to compare for treatment effect. The 
sample size may have been too small to complete a subgroup analysis for varied ethnicity 
within the study. 
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Ardabili et al19 was a double-blinded RCT, but had loss to follow up without 
intention-to-treat analysis, underpowered outcomes due to small treatment effect (i.e. loss 
to follow up and small sample size), and large CI for results. The loss to follow up was 
accounted for by authors with 5/60 patients unwilling to continue with participation, 2/60 
loss to follow up, 2/60 noncompliant, and 1/60 moving from the study parameters.19 Still, 
loss to follow up for this study was 17 percent and is likely had a significant impact on 
results. The dietary intake from patients was a form of recall bias, as the study required 
participants recall what they ingested for 3 days in order to determine if confounders 
were present.19 Although all patients were Iranian women, the authors of this study 
suggested that all patients located in the same area, 39 degrees latitude, would not have 
ultraviolet radiation as a potential confounder in the study19. Again, it is variation in 
culture and environment within this population that may have affected the results in this 
study as well as others. Participants did not receive Metformin or calcium supplements. 
Kotsa et al20 has no control population, missing data from one participant, and 
flawed measurement for the primary outcome of IR. Missing data is a question of validity 
and could potentially underestimated or overestimate the results. Surrogate outcomes 
such as lipid profile were also used to measure glucose metabolism. The flawed 
measurement for IR was not using HOMA-IR, rather; insulin secretion and insulin 
sensitivity is measured and evaluated as AUC to make suggestions regarding IR and 
insulin function.20 The CI was large and insignificant for glucose metabolism and IR. 
This study does not describe BMI as a primary outcome, but reported no change in BMI 
as a result of the study. All participants were from Greece, so there is potential for 
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population bias and confounders within this study. This study did not allow participants 
to take Metformin or calcium supplementation. 
Selimoglu et al21 has no control population, short follow up duration, small 
sample size, and does not describe hyperandrogenism as a primary outcome. This study 
measured primary outcomes with HOMA-IR for insulin resistance, but poorly measured 
insulin secretion for glucose metabolism. Androgen levels were discussed in the results 
of this study, but it is not indicated as a primary outcome or found to be correlated with 
vitamin D levels.21 Participants in this study only received one dose of vitamin D 
supplementation, without Metformin or calcium supplements, which other studies have 
allowed of their study participants. Authors described Turkish women as being more 
vitamin D deficient,21 which is potential for population bias. As Rashidi et al17 had 
shown, vitamin D in conjunction with Metformin may prove to augment the benefits of 
Metformin or calcium activity in PCOS patients, which is yet to be determined. 
Therefore, results of this study17 and others without Metformin or calcium may be 
insignificant or show that vitamin D has an insignificant effect. A longer study with 
increased vitamin D treatment may show more consistent results with other studies and 
improve treatment effect for IR and glucose metabolism, as well as observing more 
significant improvement in androgenic characteristics.  
CONCLUSION 
 
It is possible that vitamin D and calcium supplementation yields a positive 
outcome in a variety of symptoms common in PCOS, including fertility, menstruation 
regularity, weight, glucose metabolism, insulin resistance, and hyperandrogenism. The 
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studies evaluated in this review all had small sample sizes and short duration of therapy, 
so it is difficult to determine the significance of each study outcome. 
  Further long-term, RCT, prospective studies are necessary to determine if this 
supplementation is beneficial to PCOS patients. If larger studies were conducted, 
multiple subgroups analyses may be necessary to remove confounders associated with 
environment (i.e. sunlight exposure), family history, ethnicity, diet, sexual activity, and 
use of other medications. Vitamin D supplementation should be considered as a safe and 
easily accessible therapy that is relatively inexpensive in the treatment of patients with 
PCOS and vitamin D deficiency, but more studies are necessary to assess its effectiveness 
on associated PCOS symptoms and whether vitamin D supplementation should be 
administered concurrently with Metformin and/or calcium supplementation.  
Based on the GRADE criteria, the evidence in this review is of very low quality. 
Because most of the study population patients selected across these studies was vitamin 
D deficient, it is recommended they receive vitamin D supplementation. A further inquiry 
is whether serum vitamin D level needs monitoring while managing PCOS patients. 
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TABLE I.  Characteristics of Reviewed Studies and Summary of Findings, GRADE profile 
 
 
a Rashidi et al has no details of blinding and allocation, Thys-Jacobs et al has no control population, Firouzabadi et al is a case-control study without blinding. 
b Rashidi et al used surrogate outcome to correlate with possible pregnancy rates not seen in the study, therefore, follicular size/growth shown in Summary of Findings. Note: Pregnancy rate was zero among all three groups. 
c Rashidi et al lack of treatment and follow up for outcome. 
d Ardabili et al has loss of follow up without intention-to-treat analysis, Kotsa et al has no control population, missing data from participant and flawed measurement for outcome, Selimoglu et al has no control population and short follow up duration. 
e Ardabili et al has underpowered outcome due to small treatment effect (i.e. loss of follow up and small sample size), Kotsa et al used surrogate outcome for glucose metabolism. 
f  Ardabili et al has large CI, Kotsa et al shows CI as insignificant for effect, Selimoglu et al has large CI. 
g Kotsa et al has no control population, Firouzabadi et al is a case-control without blinding. 
h Kotsa et al does not describe BMI as primary outcome. 
i Firouzabadi et al has large CI.  
j Selimoglu et al has no control population and short follow up duration, Thys-Jacobs et al has no control population and flawed measurement for hyperandrogenism (objective), Firouzabadi et al is a case-control study without blinding and incomplete account for outcome. 
k Selimoglu et al does not describe hyperandrogenism as a primary outcome. 
Quality Assessment Summary of Findings 
Importance  Downgrade Criteria  Number of Patients Effect 
Quality No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
Bias Study 
Treatment 
(total) 
Placebo or no 
treatment (total) 
Relative 
Risk NNT 
Fertility  
3 
 
1 RCT 
1 Observational 
1 Case Control 
 Very Serious 
limitationsa 
Serious 
indirectnessb  
No serious 
imprecision 
Some 
inconsistenciesc No bias likely 
Rashidi et al 5/19 14/19 1.66 NNT = 9.5 
Very Low Critical Thys-Jacobs et al 2/13 n/a n/a n/a 
Firouzabadi et al 9/50 41/50 1.50 NNT = 16.7 
Menstruation irregularity 
3 
1 RCT 
1 Observational 
1 Case Control 
Very Serious 
limitationsa 
Some 
indirectnessb 
No serious 
imprecision 
Some 
inconsistenciesc No bias likely 
Rashidi et al 10/20 10/20 1.42 NNT = 6.7 
Very Low Important Thys-Jacobs et al 7/13 n/a n/a n/a 
Firouzabadi et al 35/50 15/50 1.21 NNT = 8.3 
Glucose metabolism  
3 1 RCT 2 Observational 
Very Serious 
limitationsd 
Serious 
indirectnesse 
Serious 
imprecisionf 
No serious 
inconsistencies No bias likely 
Ardabili et al n/a n/a n/a n/a 
Very Low Critical Kotsa et al n/a n/a n/a n/a 
Selimoglu et al n/a n/a n/a n/a 
Insulin resistance 
3 1 RCT 2 Observational 
No serious 
limitationsd 
Serious 
indirectnesse 
Serious 
imprecisionf 
No serious 
inconsistencies No bias likely 
Ardabili et al n/a n/a n/a n/a 
Very Low Critical Kotsa et al n/a n/a n/a n/a 
Selimoglu et al n/a n/a n/a n/a 
Weight/BMI 
2 1 Observational 1 Case Control 
Very Serious 
limitationsg 
Serious 
indirectnessh 
Serious 
imprecisioni 
No serious 
inconsistencies No bias likely 
Kotsa et al n/a n/a n/a n/a 
Very Low Critical 
Firouzabadi et al n/a n/a n/a n/a 
Hyperandrogenism (i.e. Androgen Excess) 
3 2 Observational 1 Case Control 
Very Serious 
limitationsj 
Serious 
indirectnessk 
No serious 
imprecision 
No serious 
inconsistencies No bias likely 
Selimoglu et al n/a n/a n/a n/a 
Very Low Important Thys-Jacobs et al 3/13 n/a n/a n/a 
Firouzabadi et al n/a n/a n/a n/a 
